Antibodies targeting the immunomodulatory receptor CTLA-4 have two putative mechanisms of action: direct inhibition of CLTA-4 binding to its cognate ligand and depletion of immunosuppressive regulatory T (Treg) cells via Fc-mediated immune-mediated mechanisms, mainly including ADCC and CDC.245 More importantly, the BiTEs are able to redirect T cells to specific tumor antigens and to directly activate the T cells.323 Because T cells lack Fcγ receptors, natural antibodies cannot directly recruit these T cells. The gene discussed is CTLA4; the disease is neoplasm.